Pinnacle Associates LTD Ultragenyx Pharmaceutical Inc. Transaction History

Pinnacle Associates LTD

$6.3 Billion
Q3 2024

A detailed history of Pinnacle Associates LTD transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Pinnacle Associates LTD holds 119,360 shares of RARE stock, worth $5.37 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

119,360

Previous 161,020 25.87%

Holding current value

$5.37 Million

Previous $6.62 Million 0.2%

% of portfolio

0.11%

Previous 0.11%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 25, 2024	SELL	$40.21 - $59.36 $1.68 Million - $2.47 Million	-41,660 Reduced 25.87%	119,360 $6.63 Million
Q2 2024 Jul 30, 2024	BUY	$37.42 - $51.61 $1.56 Million - $2.15 Million	41,633 Added 34.87%	161,020 $6.62 Million
Q1 2024 Apr 26, 2024	BUY	$43.02 - $53.69 $1,161 - $1,449	27 Added 0.02%	119,387 $5.57 Million
Q4 2023 Jan 19, 2024	BUY	$31.73 - $49.19 $158 - $245	5 Added 0.0%	119,360 $5.71 Million
Q3 2023 Oct 23, 2023	SELL	$34.92 - $46.66 $134,127 - $179,221	-3,841 Reduced 3.12%	119,355 $4.26 Million
Q2 2023 Jul 26, 2023	SELL	$37.35 - $52.15 $119,557 - $166,932	-3,201 Reduced 2.53%	123,196 $5.68 Million
Q1 2023 May 04, 2023	SELL	$36.99 - $48.71 $75,422 - $99,319	-2,039 Reduced 1.59%	126,397 $5.07 Million
Q4 2022 Jan 31, 2023	BUY	$33.72 - $46.33 $27,414 - $37,666	813 Added 0.64%	128,436 $5.95 Million
Q4 2022 Jan 25, 2023	SELL	$33.72 - $46.33 $94,247 - $129,492	-2,795 Reduced 2.14%	127,623 $0
Q3 2022 Oct 31, 2022	SELL	$39.96 - $66.14 $145,454 - $240,749	-3,640 Reduced 2.72%	130,418 $5.4 Million
Q2 2022 Aug 02, 2022	SELL	$45.8 - $85.4 $101,721 - $189,673	-2,221 Reduced 1.63%	134,058 $8 Million
Q1 2022 May 05, 2022	SELL	$62.2 - $84.4 $329,349 - $446,898	-5,295 Reduced 3.74%	136,279 $9.9 Million
Q4 2021 Feb 02, 2022	SELL	$73.71 - $87.86 $57,641 - $68,706	-782 Reduced 0.55%	141,574 $11.9 Million
Q3 2021 Oct 19, 2021	SELL	$77.92 - $102.4 $324,069 - $425,881	-4,159 Reduced 2.84%	142,356 $12.8 Million
Q2 2021 Aug 02, 2021	BUY	$92.19 - $115.71 $112,932 - $141,744	1,225 Added 0.84%	146,515 $14 Million
Q1 2021 May 12, 2021	SELL	$106.9 - $167.73 $1.4 Million - $2.19 Million	-13,065 Reduced 8.25%	145,290 $16.5 Million
Q4 2020 Jan 26, 2021	SELL	$84.4 - $177.39 $787,536 - $1.66 Million	-9,331 Reduced 5.56%	158,355 $21.9 Million
Q3 2020 Oct 23, 2020	SELL	$72.98 - $90.0 $475,318 - $586,170	-6,513 Reduced 3.74%	167,686 $13.8 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $8.39 Million - $14 Million	-178,771 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$33.8 - $62.9 $1.14 Million - $2.11 Million	-33,616 Reduced 15.83%	178,771 $7.94 Million
Q4 2019 Feb 03, 2020	BUY	$36.08 - $45.83 $5.03 Million - $6.39 Million	139,380 Added 190.91%	212,387 $9.07 Million
Q3 2019 Nov 08, 2019	BUY	$42.5 - $63.11 $3.1 Million - $4.61 Million	73,007 New	73,007 $3.12 Million

Others Institutions Holding RARE

# of Institutions

326

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.15B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.

Account

Pinnacle Associates LTD Ultragenyx Pharmaceutical Inc. Transaction History